A prospective, randomized, double blind, placebo controlled clinical study to evaluate the efficacy and safety of Bilberry extract capsules (180mg) in the eye health of human adults.

A prospective, randomized, double blind, placebo controlled clinical study to evaluate the efficacy and safety of Bilberry extract capsules (180mg) in the eye health of human adults. - A clinical study to evaluate the efficacy and safety of Bilberry extract capsules in the eye health of human adults.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024204

Enrollment

Registered

2016-09-28

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult

Interventions

One Bilberry extract(Bilcyan) capsule(180mg) twice a day (before breakfast and dinner) for 12 weeks One placebo capsule twice a day (before breakfast and dinner) for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Males and females with age 30-60year 2)Subjects who are able to provide informed consent 3)Patients willing and able to comply with all trial requirements 4)Subjects having at least anyone of the following condition; Eye strain/redness/watering/burning sensation/itching in the eyes/acuity of vision

Exclusion criteria

Exclusion criteria: 1)Subject having the crystalline lens removed from the study eye or the crystalline lens removed and replaced with an intraocular lens(IOL) implant in the left eye 2)Subject clinically diagnosed with cataracts in the study eye 3)Subject having a fluorescence angiogram within the last six months 4)Pregnant or lactating women 5)Subject undergone a treatment using photodynamic drugs within the last year 6)Subject having Type I or II diabetes or is not deemed healthy from Demographic and Health Questionnaire or the comprehensive eye exam 7)Subject fit with contact lens within the last 30 days

Design outcomes

Primary

Measure	Time frame
Changes in visual capacity evaluated by standard comprehensive ophthalmic examination(Snellen test) before and after ingestion(12 weeks) Changes in eye conditions like Eye strain/redness/watering/burning sensation/itching in the eye before and after ingestion(12 weeks)	—

Secondary

Measure	Time frame
Incidence and rate of adverse events after ingestion(12 weeks)	—

Countries

Asia(except Japan)

Contacts

Public ContactMomoko Imai

Vidya Japan K.K. Sales

m-imai@vidyajapan.co.jp03-6721-0430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026